137 related articles for article (PubMed ID: 29319843)
21. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis.
Steinmetz T; Eliakim-Raz N; Goldberg E; Leibovici L; Yahav D
Clin Microbiol Infect; 2015 Jul; 21(7):665-73. PubMed ID: 25887712
[TBL] [Abstract][Full Text] [Related]
22. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic Monitoring of Vancomycin in Cystic Fibrosis: Is It Time to Move Past Trough Concentrations?
Fusco NM; Prescott WA; Meaney CJ
Pediatr Infect Dis J; 2019 Mar; 38(3):258-262. PubMed ID: 29742643
[TBL] [Abstract][Full Text] [Related]
24. Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis.
Durham SH; Garza KB; Eiland LS
Am J Health Syst Pharm; 2016 Jul; 73(13):969-74. PubMed ID: 27325878
[TBL] [Abstract][Full Text] [Related]
25. Applicability of hemodialysis clearance parameter for vancomycin therapeutic drug monitoring during continuous hemodiafiltration in an infant.
Shiohira H; Isagawa S; Yamada S; Sunagawa S; Nakamatsu M; Yonaha F; Hokama N; Fujita J; Nakamura K
Pharmazie; 2018 Dec; 73(12):737-739. PubMed ID: 30522560
[TBL] [Abstract][Full Text] [Related]
26. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.
Chung J; Oh JM; Cho EM; Jang HJ; Hong SB; Lim CM; Koh YS
Anaesth Intensive Care; 2011 Nov; 39(6):1030-7. PubMed ID: 22165354
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.
Moffett BS; Morris J; Munoz F; Arikan AA
Eur J Clin Pharmacol; 2019 Aug; 75(8):1089-1097. PubMed ID: 30937470
[TBL] [Abstract][Full Text] [Related]
28. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
Parra-Ruiz J; Tomas-Jiménez C; Muñoz-Medina L; Hernández-Quero J
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
[No Abstract] [Full Text] [Related]
29. Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.
Bernstein AT; Leigh MW; Goralski JL; Esther CR; McKinzie CJ
J Cyst Fibros; 2018 Nov; 17(6):e48-e50. PubMed ID: 30170755
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis.
Housman ST; Bhalodi AA; Shepard A; Nugent J; Nicolau DP
J Am Podiatr Med Assoc; 2015 Sep; 105(5):381-8. PubMed ID: 26429605
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
32. Evolution of empiric vancomycin dosing in a neonatal population.
Radu L; Bengry T; Akierman A; Alshaikh B; Yusuf K; Dersch-Mills D
J Perinatol; 2018 Dec; 38(12):1702-1707. PubMed ID: 30341404
[TBL] [Abstract][Full Text] [Related]
33. Continuous vancomycin in a pediatric cystic fibrosis patient.
McKinzie CJ; Esther CR; Vece TJ
Pediatr Pulmonol; 2018 Jan; 53(1):E4-E5. PubMed ID: 29193836
[TBL] [Abstract][Full Text] [Related]
34. Empirical Vancomycin Dosing in Pediatric Patients with Congenital Heart Disease and the Impact of Cardiopulmonary Bypass on Trough Concentrations.
Thomas CA; Picone A; Menon S; Willis BC
Pharmacotherapy; 2017 Nov; 37(11):1341-1346. PubMed ID: 28833385
[TBL] [Abstract][Full Text] [Related]
35. Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
Yoo RN; Kim SH; Lee J
J Korean Med Sci; 2017 Jan; 32(1):22-28. PubMed ID: 27914127
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of vancomycin dosing for complicated infections in pediatric patients.
Durham SH; Simmons ML; Mulherin DW; Foland JA
Hosp Pediatr; 2015 May; 5(5):276-81. PubMed ID: 25934812
[TBL] [Abstract][Full Text] [Related]
38. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
39. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
Patel K; Crumby AS; Maples HD
Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
[TBL] [Abstract][Full Text] [Related]
40. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
